Alnylam Pharmaceuticals has new data from the open-label extension (OLE) period of the ENVISION Phase 3 study This shows the long-term therapeutic benefit of givosiran in patients with acute hepatic porphyria (AHP)—an orphan disease that can be life threatening. The results were presented by study investigator Eliane Sardh, MD, during a webinar hosted by Alnylam. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!